cell transplantation

[Experimental Hematology] Scientists present a summary and discussion of the implications of new approaches to improve hematopoietic stem cell transplantation-based therapy.

[BMC Cancer] Investigators retrospectively collected the clinical data of 48 patients with mixed-lineage leukemia (MLL)-partial tandem duplications (PTD) acute myeloid leukemia or myelodysplastic syndrome with excess blasts who underwent allogeneic hematopoietic stem cell transplantation (HSCT) in Peking University People’s Hospital.

[Blood Advances] Scientists summarize the literature on post-hematopoietic stem cell transplantation immune-mediated anemia with a focus on ABO and non-ABO blood group incompatibility, described the underlying mechanism of anemia, and outlined preventive and treatment approaches.

[Stem Cell Research & Therapy] Human cord blood CD34+ cells were co-cultured with mesenchymal stromal cells (MSC) wild type or Hypoxia-inducible factor-1α-MSC (4:1) for 72 hours. Then, viability, cell cycle, ROS expression and immunophenotyping of key molecules involved in engraftment were evaluated by flow cytometry in CD34+ cells.

[Scientific Reports] Scientists found that cytokine-specific autoantibodies (c-aAb) levels were stable over the course of hematopoietic stem cell transplantation, including at high titres, with few individuals seeming to acquire high-titre levels of c-aAbs.

[CoImmune, Inc.] CoImmune, Inc. announced that results from a Phase I/II clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company’s chimeric antigen receptor modified cytokine induced killer cell platform, demonstrated sustained responses in pediatric and adult patients with B-cell acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic stem cell transplantation.